Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer (stage IIIB to IV) that cannot be removed by surgery.
- Your cancer has an EGFR mutation (exon 19 deletion or L858R point mutation) and high PD-L1 (at least 50% by a central lab test).
- You have not had any prior chemotherapy, targeted therapy, or immunotherapy for advanced disease.
- You have not used any EGFR or MET targeted therapy before.
- You are in good overall health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests whether combining an EGFR-targeting drug (furmonertinib) with either ablation or radiation therapy can help patients with early-stage lung cancer who cannot have surgery or choose not to. The goal is to see if this combination approach works better than treatment alone.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.